Athira Pharma initiates new Phase II/III study of ATH-1017 in mild to moderate AD

On 1 October, Athira Pharma, a clinical-stage biopharmaceutical company aiming to restore neuronal health in neurodegenerative diseases announced the initiation of the LIFT-AD Phase II/III study evaluating ATH-1017, an once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease (AD). The LIFT-AD study is a randomised, double-blind and placebo-controlled Phase II/III study evaluating the safety and efficacy of ATH-1017 in people with mild-to-moderate AD. The company expects to recruit approximately 300 research participants in the US and Australia.

https://www.athira.com/athira-pharma-announces-initiation-of-patient-dosing-for-the-lift-ad-study-a-phase-2-3-clinical-trial-to-evaluate-ath-1017-for-treatment-of-mild-to-moderate-alzheimers-disease/